An interventional study of MRI in Severe Aortic Valve Stenosis, sponsored by IRCCS Policlinico S. Donato. Recruiting at 2 sites in Italy. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 27th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2025, is one of 40 with no phase, reaches primary completion later than 32 of the 53 other live ones, and was the 106th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:
University Hospital of Ferrara · Sites in Italy
Ages 75+
University Hospital of Ferrara · Sites in Italy
Azienda Ospedaliera "Sant'Andrea" · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 47 interventional studies, 500 across the 71 observational. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 118 have an industry lead sponsor. The 10 most frequent:
IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.
IRCCS Policlinico S. Donato has 5 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Valve Stenosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07620925Azienda Ospedaliera "Sant'Andrea"Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study | 2026-12-31 |
| NCT06859255IRCCS Policlinico S. DonatoIn-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic Stenosis With Small Annulus, Followed by In-vivo Validation | 2027-02-07 |
| NCT05779787Niguarda HospitalCOronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY) | 2027-02-15 |
| NCT05751577Azienda Usl di BolognaTRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial | 2027-03-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The general objective of this study is to compare in vitro and in vivo the hemodynamic performance of different types of aortic valve prostheses and possible surgical implantation techniques.
The study involves the collection of data deriving from tests and procedures foreseen by normal clinical practice, including a transthoracic color Doppler echocardiogram, to which is added a 4DFlow cardiac MRI (magnetic resonance imaging) without contrast medium, to be performed between 1 and 3 months after the operation.
The study will last 24 months and the patients involvement will end approximately 1-3 months after the intervention.
There are no direct benefits expected from participation in the study. However, the instrumental data obtained by echocardiogram and Magnetic Resonance Imaging will be useful for monitoring the medium-term surgical outcome of patients after surgery.
The goal of the study is testing hydrodynamic performances of various surgical and transcatheter valve prostheses, also according to the technique of implantation. A dedicated Magnetic Resonance Imaging (MRI) compatible mock circulation simulator will be implemented, including a circuit filled with blood-alike fluid, a pulsatile pump, and 3D printed silicon phantoms of ascending aorta.
Data collection will focus on structural changes of prostheses in response to flow, including leaflet motion, gradients and flows across the valve, taken either by direct pressure measurements and 4D Flow MRI. As second step, trans-valvular gradients and valve performance in patients implanted with the same tested valves will be measured by echocardiogram and 4D Flow MRI.
Degenerative aortic valve stenosis is a common disease in people >65 years, with an estimated rate approaching 10% in Western countries. Despite progress in diagnosis and therapy, invasive treatments still represent the only definitive option, including surgical aortic valve replacement (SAVR) and more recently less-invasive transcatheter aortic valve replacement (TAVR).
Patients with small aortic annulus constitute a challenging subset, where the need to minimize both procedural and longterm risk entwine with that of avoiding patient-prosthesis mismatch (PPM) and structural valve deterioration (SVD). The common denominator appears to be blood flow, which has demonstrated to play a pivotal role in late complications. In fact, PPM is associated with earlier structural valve dysfunction and higher long-term mortality. To obtain larger effective orifice area, surgeons must consider many different procedures (annular enlargement), valve models (stented valves, subcoronary stentless valves, or rapid deployment valves) or different techniques of valve suturing. However, in the literature, there is no clear indication to the ideal strategy of treatment so far. Heart valve prostheses generate turbulent flow in the aortic root and the ascending aorta. Hydrodynamic instabilities and turbulent flow may produce clinically adverse events. Therefore, a thorough evaluation of hemodynamic and flow conditions should be tested, to provide the most effective treatment strategy for each patient.
Both units regularly perform surgical as well as percutaneous aortic valve replacements: patients from both centres will be enrolled to evaluate post-implant valve performances by echocardiogram and MR imaging.
Both units will have an equal contribution with regard to study design, collection of patients, data, analysis and interpretation of data, drawing of manuscript.
In addition, Unit 1 will set up and run the mock circulation system for in-vitro tests.
Valve performance can be tested using advanced cardiovascular imaging techniques combined with in vitro testing platforms. On the one hand, three-dimensional time-resolved MRI with three-directional velocity encoding (4D Flow MRI) offers the possibility to assess blood flow patterns enabling full volumetric coverage of the region of interest, a detailed 3D visualization of the flow pattern and post hoc quantification of several hemodynamic metrics. On the other hand, the in vitro setting is the gold-standard approach to consistently investigate the blood pressure variability (BPV) hemodynamics in a fully controlled environment, through ad hoc system sensorization, under a standardized setup and protocol of measurements, with no influence by confounding in vivo factors. The combination of these two techniques allows for the characterization of selected heart valves prostheses.
The 3D and Computer Simulation Laboratory (in short C3DLab) is equipped with facilities specifically devoted to 3D medical image processing, including dedicated commercial softwares for 3D anatomic reconstructions (e.g., Mimics Innovation Suite, Materialise). Dedicated workstations (Fujitsu CELSIUS J550/2, Intel® Core i7-7700 CPU 3.60 GHz with 32 GB RAM) are available for pre- and post-processing. C3DLab facilities also include a high-end 3D printer (MJP2500 Plus, by 3D Systems) to obtain deformable and suturable phantoms of cardiovascular organs and a highly accurate 3D scanner (Artec Micro, by Artec 3D) to obtain the digital model of implantable devices or small cardiovascular structures. MRI, and specifically 4D Flow MRI, can be performed at IRCCS Policlinico San Donato using a 1.5 T MAGNETOM Aera machine (Siemens Healthcare, Erlangen, Germany) scanner.
Specific aim 1 To classify and compare valves according to actual measured size and haemodynamic performance (pressure gradients and derived measures), rather than label size.
In the surgical group, the two most common techniques of implantation will be compared: intra-annular vs supra-annular positioning, obtained by placing interrupted everting and non-everting pledgeted sutures, respectively. Valve prostheses will be divided in three groups and tested accordingly:
Transcatheter valve prostheses will be divided in two major groups:
Specific aim 2 The investigator's assumption is that hemodynamic performance may not be the only factor to consider in valve choice, but others may influence long-term durability and risk of device-related complications such as early degeneration, thrombo-embolic events, and endocarditis.
Therefore, analysis and classification of tested prosthetic valves will be carried out, by flow patterns, shear forces and turbulences acting through the valve opening, structures and on the leaflets.
Three-dimensional time-resolved MRI with three-directional velocity encoding (4D Flow MRI) offers the possibility to assess blood flow patterns enabling full volumetric coverage of the region of interest.
The 4D Flow MRI sequence includes a prototype time-resolved 3D gradient echo sequence with three-directional velocity encoding. Several fluid dynamic parameters can be extracted from 4D Flow MRI, using advanced numerical schemes, including pressure gradients, kinetic energy and viscous energy loss. Additionally, streamlines and pathlines can be used to visually assess blood flow trajectories.
Specific aim 3 In-vivo validation of results. Measurements will be taken from an adequate number of patients implanted with the same valve types and models that were tested in-vitro.
Transthoracic echocardiography is an easy, cheap, and widely adopted technique, representing the standard of care in postoperative follow-up of patients with prosthetic valves. The critical aspect for complete prosthetic evaluation are:
Regarding 4D Flow MRI, collected parameters will be similar to those analysed in-vitro: pressure gradients, kinetic energy, viscous energy loss, as well as streamlines and pathlines.
The investigators hypothesise that the system allows to predict flow dynamics and its alterations, better than those already existing, and more closely reflects the haemodynamic performance of in-vivo implants.
The aim is to give an unbiased insight on which treatment is best in different subsets of patients, to help guide clinical decisions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Inclusion criteria: * evaluation of patients who underwent SAVR or TAVI for severe aortic stenosis * implanted with valve models and sizes among those which we evaluated in vitro. Exclusion criteria: * treated or untreated aortic root/ascending aorta aneurysm * preoperative aortic regurgitation more than moderate * recent (\<12 weeks)/ concomitant revascularization or recent (\<12 weeks) ACS Timing of trans-thoracic echocardiography (TTE) and MRI: 1 to 3 months after SAVR/TAVR. Intervention: MRI, it is not clinical practice during 1 month follow-up. Clinical Variables: in order to reduce clinical bias in the comparison of the two populations, at the moment of TTE exam, blood pressure, heart rate and haemoglobin values will be recorded.
Diagnostic Test: MRI
The patients will be undergo to a MRI without contrast after 1 month from the procedure/surgery to test the hwmodynamic performance 4d flow in the implanted valve
Bench tests performance
Pressure gradient after valve implantation in vitro
Time frame: 24 months
MRI in vitro
Blood flow pattern of aortic in vitro models under 4D flow MRI
Time frame: 24 months
Echo in vivo
Morphology of the bioprosthetic valve leaflets will be evaluated in vivo through an Echo
Time frame: 24 months
Echo in vivo
Motiliy of the bioprosthetic valve leaflets will be evaluated in vivo through an Echo
Time frame: 24 months
RMN in vivo
Blood flow pattern of implanted valves will be evaluated in vivo through a MRI 4 flow
Time frame: 24 months
Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 24 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.